Internet-delivered Cognitive-behaviour Therapy for Adolescents With Body Dysmorphic Disorder
Primary Purpose
Body Dysmorphic Disorders, Dysmorphophobia
Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Exposure and response prevention (ERP)
Sponsored by
About this trial
This is an interventional treatment trial for Body Dysmorphic Disorders focused on measuring Body dysmorphic disorder, Dysmorphophobia, Cognitive-behavioral therapy, Internet-delivered treatments, Adolescents, Treatment outcomes
Eligibility Criteria
Inclusion Criteria:
- Age 12 to 17 years, confirmed by the caregiver and subsequently by the patient record system Take Care.
- A diagnosis of BDD, based on the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), confirmed by the assessor at the pre-treatment assessment.
- A total BDD severity score on the BDD-YBOCS-A ≥24. confirmed by the clinician-reported BDD-YBOCS-A performed at the pre-treatment assessment.
- A minimum of one available caregiver (parent) to support the child/adolescent throughout the treatment. Confirmed by the caregiver at the telephone screening or/and pre-treatment assessment.
- Regular access to a desktop or laptop computer connected to the Internet, with the ability to receive e-mails, as well as a mobile phone to receive SMS (one of each per family is enough). Confirmed by the caregiver at the telephone screening or/and pre-treatment assessment.
Exclusion Criteria:
- Previous CBT for BDD for a minimum of eight sessions with a qualified therapist within the 12 months prior to assessment. Confirmed by the caregiver at the telephone screening and/or pre-treatment assessment.
- Simultaneous psychological treatment for BDD, confirmed by the caregiver at the telephone screening and/or pre-treatment assessment.
- Initiation, adjustment or change of any selective serotonin reuptake inhibitors (SSRI) within the six weeks prior to the pre-treatment assessment. Confirmed by the caregiver at the telephone screening and/or pre-treatment assessment.
- A diagnosis of organic brain disorder, intellectual disability or a psychiatric disorder (such as psychosis, bipolar disorder or eating disorder) that could interfere with the completion of the treatment. Confirmed by the caregiver at the telephone screening and/or pre-treatment assessment, with help of information from the caregiver and the child/adolescent, and the MINI-KID interview.
- Immediate risk to self or others requiring urgent medical attention, such as current risk of suicide or self-injurious behaviours. Confirmed by the assessor at the telephone screening and/or face-to-face or video conference pre-treatment assessment, with help of information from the caregiver and the child/adolescent, and the suicide questions on the MINI-KID interview.
- Child and caregiver not able to read and communicate in Swedish. Confirmed by the caregiver or assessor at the telephone screening and/or pre-treatment assessment.
Sites / Locations
- Karolinska Institutet
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Internet-delivered cognitive-behaviour therapy for adolescents with body dysmorphic disorder
Arm Description
Cognitive-behaviour therapy, Exposure and response prevention (ERP)
Outcomes
Primary Outcome Measures
Treatment credibility questionnaire
Questionnaire developed by the research team. Used to assess treatment credibility. Separate versions for the child/adolescent and the parent are used. Range: 0-12, high scores means better outcome.
Treatment satisfaction questionnaire
Questionnaire developed by the research team. Used to assess treatment satisfaction. Separate versions for the child/adolescent and the parent are used. Range: 0-36, high scores means better outcome.
internet intervention Patient Adherence Scale (iiPAS) Mid-treatment
Used to assess the child/adolescent's adherence to the internet-delivered treatment. Range: 0-20, high scores means better outcome.
internet intervention Patient Adherence Scale (iiPAS) Post-treatment
Used to assess the child/adolescent's adherence to the internet-delivered treatment. Range: 0-20, high scores means better outcome.
Negative effects questionnaire - Mid-treatment
Used to assess side effects/adverse events for the child/adolescent. Parent-reported. Range: 0-100, low scores means better outcome.
Negative effects questionnaire - Post-treatment
Used to assess side effects/adverse events for the child/adolescent. Parent-reported. Range: 0-100, low scores means better outcome.
Negative effects questionnaire - 3 months follow-up
Used to assess side effects/adverse events for the child/adolescent. Parent-reported. Range: 0-100, low scores means better outcome.
Ease of recruitment: Time to recruit
Time to recruit 20 participants.
Ease of recruitment: Amount of participants accepting participation after screening
Amount of participants accepting/declining participation after telephone screening
Ease of recruitment: Amount of participants accepting participation after assessment
Amount of participants accepting/declining participation after initial assessment.
Number of completed chapters in the internet treatment platform
Number of completed chapters is automatically logged in the internet treatment platform. Separate data for children and parents.
Participant retention
Number of included participants completing treatment.
Secondary Outcome Measures
Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder, Adolescent version (BDD-YBOCS-A)
Used to assess BDD symptom severity. Clinician-rated, semi-structured interview. Range: 0-48, low scores means better outcome.
Clinical Global Impression - Severity (CGI-S)
Used to provide an overall rating of the BDD severity. Clinician-rated. Range: 1-7, low scores means better outcome.
Clinical Global Impression - Improvement (CGI-I)
Used to assess global improvement. Clinician-rated. Range: 1-7, low scores means better outcome.
Children's Global Assessment Scale (CGAS)
Used to assess global improvement. Clinician-rated. Range: 1-100, high scores means better outcome.
Appearance Anxiety Index (AAI)
A self-reported measure that covers cognitions and behaviours typical of BDD. Range: 0-40, low scores means better outcome.
Short Mood and Feeling Questionnaire - child version (SMFQ) + additional suicide item
Used to assess depressive symptoms and suicidal ideation. Child/adolescent-reported. Range: 0-29, low scores means better outcome.
Short Mood and Feeling Questionnaire - parental version (SMFQ) + additional suicide item
Used to assess depressive symptoms and suicidal ideation in the adolescent. Parent-reported. Range: 0-29, low scores means better outcome.
The Work and Social Adjustment Scale - Youth Version (WSAS-Y)
A self-reported instrument assessing functional impairment. Range: 0-40, low scores means better outcome.
The Work and Social Adjustment Scale - Parent Version (WSAS-P)
A parent-reported instrument assessing functional impairment in the adolescent. Range: 0-40, low scores means better outcome.
CRAFFT (acronym for the key words Car, Relax, Alone, Forget, Friends and Trouble)
A short self-reported instrument used to identify substance use and substance use disorder. Range: 0-6, low scores means better outcome.
KIDSCREEN-10
Used to assess quality of life. Separate versions for the child/adolescent and the parent are used. Range: 10-50, high scores means better outcome.
Full Information
NCT ID
NCT05078320
First Posted
September 20, 2021
Last Updated
October 3, 2023
Sponsor
Karolinska Institutet
1. Study Identification
Unique Protocol Identification Number
NCT05078320
Brief Title
Internet-delivered Cognitive-behaviour Therapy for Adolescents With Body Dysmorphic Disorder
Official Title
Internet-delivered Cognitive-behaviour Therapy for Adolescents With Body Dysmorphic Disorder: A Feasibility Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
October 22, 2021 (Actual)
Primary Completion Date
September 6, 2022 (Actual)
Study Completion Date
June 26, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska Institutet
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this trial is to investigate whether a therapist-guided Internet-delivered cognitive behaviour therapy (ICBT) programme is feasible for adolescents with body dysmorphic disorder (BDD). The aim is to evaluate feasibility and provide preliminary efficacy data.
Detailed Description
Rationale for study: BDD is a prevalent and impairing condition that can be effectively treated with cognitive-behaviour therapy (CBT). However, CBT for BDD is a highly specialised treatment and a majority of adolescents do not have access to it. ICBT can be a way to increase the availability of effective psychological treatments. No study to date has evaluated the feasibility of ICBT for adolescent BDD, but the experience in adults with BDD treated with ICBT is encouraging.
Objectives: To investigate whether a therapist-guided Internet-delivered cognitive behaviour therapy (ICBT) programme is feasible for adolescents with body dysmorphic disorder (BDD). Specifically, the aim is to:(a) establish participant retention, ease of recruitment, acceptability, credibility, and satisfaction, (b) evaluate potential adverse events, and (c) provide preliminary efficacy data.
Trial design and methods: Participants will be recruited nationally and will be offered 12 modules of ICBT for BDD, delivered over a period of 14 weeks. Participants will be assessed before, during, and after treatment, and up to 12 months after the end of the treatment. ICBT non-responders, assessed at post-treatment and one-, two-, and three-months after completing treatment, will be offered CBT delivered via video format (at post-treatment and after the 1MFU and the 2MFU) or traditional face-to-face (F2F) CBT at the OCD and Related Disorders Clinic for Children and Adolescents in Stockholm (after the 3MFU).
The primary outcome is feasibility, as measured by examining rates of participant retention, treatment completion and adherence to treatment content, treatment acceptability, treatment credibility, treatment satisfaction and adverse events during the treatment.
Secondary outcomes include improvement in clinician-reported BDD symptoms, as well as improvement in other clinical measures assessing disorder severity, disorder improvement, self-reported BDD symptoms, depressive symptoms, and functional impairment.
Sample: 20 adolescents and their primary caregivers.
Statistical analysis: Retention, acceptability, credibility, and treatment satisfaction. For retention and acceptability, information on ease of recruitment, number of completed modules, and attrition rates will collected and presented in a descriptive manner. Results from a credibility scale will be summarized in group means and standard deviations. Results from a treatment satisfaction scale will be summarized in group means and standard deviation. Potential adverse events: Type and impact of all potential adverse events will be measured with a specific scale and presented descriptively. Preliminary efficacy: Clinical measures of treatment outcomes will be measured via clinician-reported and self- and parent-reported measures and analysed through linear mixed models to detect within group change over time. Within-group effect sizes will be estimated with Cohen's d. Treatment response: The proportion of treatment responders will be calculated. Treatment response will be defined as a ≥30% reduction on the BDD-YBOCS-A, respective to the baseline score. Further, the investigators will also calculate how many participants are on full or partial symptom remission, defined as a score ⩽16 on the BDD-YBOCS-A.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Body Dysmorphic Disorders, Dysmorphophobia
Keywords
Body dysmorphic disorder, Dysmorphophobia, Cognitive-behavioral therapy, Internet-delivered treatments, Adolescents, Treatment outcomes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Internet-delivered cognitive-behaviour therapy for adolescents with body dysmorphic disorder
Arm Type
Experimental
Arm Description
Cognitive-behaviour therapy, Exposure and response prevention (ERP)
Intervention Type
Behavioral
Intervention Name(s)
Exposure and response prevention (ERP)
Intervention Description
The treatment is Internet-delivered and therapist-guided, involving both the adolescent and at least one parent. The treatment consists of two separate sets of modules, one for the adolescent and one for the parent, each with separate logins. The ICBT intervention consists of 12 modules, delivered over a maximum of 14 weeks.
The main goal of treatment is to help the young person to stop avoiding anxiety-provoking situations by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals, known as response prevention. Every module also contains homework tasks that mainly consists of exposure and response prevention (ERP).
Parents are also often involved in the patients' rituals and avoidant behaviours (known as family accommodation), which may contribute to maintain the BDD symptoms. Involving parents facilitates modification of these unhelpful patterns.
Primary Outcome Measure Information:
Title
Treatment credibility questionnaire
Description
Questionnaire developed by the research team. Used to assess treatment credibility. Separate versions for the child/adolescent and the parent are used. Range: 0-12, high scores means better outcome.
Time Frame
Mid-treatment (3 weeks post-baseline)
Title
Treatment satisfaction questionnaire
Description
Questionnaire developed by the research team. Used to assess treatment satisfaction. Separate versions for the child/adolescent and the parent are used. Range: 0-36, high scores means better outcome.
Time Frame
3-month follow-up.
Title
internet intervention Patient Adherence Scale (iiPAS) Mid-treatment
Description
Used to assess the child/adolescent's adherence to the internet-delivered treatment. Range: 0-20, high scores means better outcome.
Time Frame
Mid-treatment (6 weeks post-baseline)
Title
internet intervention Patient Adherence Scale (iiPAS) Post-treatment
Description
Used to assess the child/adolescent's adherence to the internet-delivered treatment. Range: 0-20, high scores means better outcome.
Time Frame
Week 14.
Title
Negative effects questionnaire - Mid-treatment
Description
Used to assess side effects/adverse events for the child/adolescent. Parent-reported. Range: 0-100, low scores means better outcome.
Time Frame
Week 6
Title
Negative effects questionnaire - Post-treatment
Description
Used to assess side effects/adverse events for the child/adolescent. Parent-reported. Range: 0-100, low scores means better outcome.
Time Frame
Week 14
Title
Negative effects questionnaire - 3 months follow-up
Description
Used to assess side effects/adverse events for the child/adolescent. Parent-reported. Range: 0-100, low scores means better outcome.
Time Frame
3 months follow-up
Title
Ease of recruitment: Time to recruit
Description
Time to recruit 20 participants.
Time Frame
From start of recruitment until 20 participants have been included. Anticipated time frame: 2-3 months
Title
Ease of recruitment: Amount of participants accepting participation after screening
Description
Amount of participants accepting/declining participation after telephone screening
Time Frame
From start of recruitment until 20 participants have been included. Anticipated time frame: 2-3 months
Title
Ease of recruitment: Amount of participants accepting participation after assessment
Description
Amount of participants accepting/declining participation after initial assessment.
Time Frame
From start of recruitment until 20 participants have been included. Anticipated time frame: 2-3 months
Title
Number of completed chapters in the internet treatment platform
Description
Number of completed chapters is automatically logged in the internet treatment platform. Separate data for children and parents.
Time Frame
Week 14
Title
Participant retention
Description
Number of included participants completing treatment.
Time Frame
Week 14.
Secondary Outcome Measure Information:
Title
Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder, Adolescent version (BDD-YBOCS-A)
Description
Used to assess BDD symptom severity. Clinician-rated, semi-structured interview. Range: 0-48, low scores means better outcome.
Time Frame
Baseline; week 14; 1-, 2-, 3-, 6- and 12-month follow-up.
Title
Clinical Global Impression - Severity (CGI-S)
Description
Used to provide an overall rating of the BDD severity. Clinician-rated. Range: 1-7, low scores means better outcome.
Time Frame
Baseline; week 14; 3-, 6- and 12-month follow-up.
Title
Clinical Global Impression - Improvement (CGI-I)
Description
Used to assess global improvement. Clinician-rated. Range: 1-7, low scores means better outcome.
Time Frame
Week 14; 3-, 6- and 12-month follow-up.
Title
Children's Global Assessment Scale (CGAS)
Description
Used to assess global improvement. Clinician-rated. Range: 1-100, high scores means better outcome.
Time Frame
Baseline; week 14; 3-, 6- and 12-month follow-up.
Title
Appearance Anxiety Index (AAI)
Description
A self-reported measure that covers cognitions and behaviours typical of BDD. Range: 0-40, low scores means better outcome.
Time Frame
Baseline; week 3, 6, 9, 14; 3-, 6- and 12-month follow-up.
Title
Short Mood and Feeling Questionnaire - child version (SMFQ) + additional suicide item
Description
Used to assess depressive symptoms and suicidal ideation. Child/adolescent-reported. Range: 0-29, low scores means better outcome.
Time Frame
Baseline; week 3, 6, 9, 14; 3-, 6- and 12-month follow-up.
Title
Short Mood and Feeling Questionnaire - parental version (SMFQ) + additional suicide item
Description
Used to assess depressive symptoms and suicidal ideation in the adolescent. Parent-reported. Range: 0-29, low scores means better outcome.
Time Frame
Baseline; week 3, 6, 9, 14; 3-, 6- and 12-month follow-up.
Title
The Work and Social Adjustment Scale - Youth Version (WSAS-Y)
Description
A self-reported instrument assessing functional impairment. Range: 0-40, low scores means better outcome.
Time Frame
Baseline; week 6, 14; 3-, 6- and 12-month follow-up.
Title
The Work and Social Adjustment Scale - Parent Version (WSAS-P)
Description
A parent-reported instrument assessing functional impairment in the adolescent. Range: 0-40, low scores means better outcome.
Time Frame
Baseline; week 6, 14; 3-, 6- and 12-month follow-up.
Title
CRAFFT (acronym for the key words Car, Relax, Alone, Forget, Friends and Trouble)
Description
A short self-reported instrument used to identify substance use and substance use disorder. Range: 0-6, low scores means better outcome.
Time Frame
Baseline; week 14; 3-, 6- and 12-month follow-up.
Title
KIDSCREEN-10
Description
Used to assess quality of life. Separate versions for the child/adolescent and the parent are used. Range: 10-50, high scores means better outcome.
Time Frame
Baseline; week 14; 3-, 6- and 12-month follow-up.
Other Pre-specified Outcome Measures:
Title
Therapist platform time
Description
Therapist platform time is automatically logged in the internet treatment platform. Separate data for children and parents.
Time Frame
Week 14
Title
Therapist telephone time
Description
Therapist telephone time is manually logged in a spreadsheet throughout the trial. Separate data for children and parents.
Time Frame
Week 14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 12 to 17 years, confirmed by the caregiver and subsequently by the patient record system Take Care.
A diagnosis of BDD, based on the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), confirmed by the assessor at the pre-treatment assessment.
A total BDD severity score on the BDD-YBOCS-A ≥24. confirmed by the clinician-reported BDD-YBOCS-A performed at the pre-treatment assessment.
A minimum of one available caregiver (parent) to support the child/adolescent throughout the treatment. Confirmed by the caregiver at the telephone screening or/and pre-treatment assessment.
Regular access to a desktop or laptop computer connected to the Internet, with the ability to receive e-mails, as well as a mobile phone to receive SMS (one of each per family is enough). Confirmed by the caregiver at the telephone screening or/and pre-treatment assessment.
Exclusion Criteria:
Previous CBT for BDD for a minimum of eight sessions with a qualified therapist within the 12 months prior to assessment. Confirmed by the caregiver at the telephone screening and/or pre-treatment assessment.
Simultaneous psychological treatment for BDD, confirmed by the caregiver at the telephone screening and/or pre-treatment assessment.
Initiation, adjustment or change of any selective serotonin reuptake inhibitors (SSRI) within the six weeks prior to the pre-treatment assessment. Confirmed by the caregiver at the telephone screening and/or pre-treatment assessment.
A diagnosis of organic brain disorder, intellectual disability or a psychiatric disorder (such as psychosis, bipolar disorder or eating disorder) that could interfere with the completion of the treatment. Confirmed by the caregiver at the telephone screening and/or pre-treatment assessment, with help of information from the caregiver and the child/adolescent, and the MINI-KID interview.
Immediate risk to self or others requiring urgent medical attention, such as current risk of suicide or self-injurious behaviours. Confirmed by the assessor at the telephone screening and/or face-to-face or video conference pre-treatment assessment, with help of information from the caregiver and the child/adolescent, and the suicide questions on the MINI-KID interview.
Child and caregiver not able to read and communicate in Swedish. Confirmed by the caregiver or assessor at the telephone screening and/or pre-treatment assessment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lorena Fernández de la Cruz, PhD
Organizational Affiliation
Karolinska Institutet
Official's Role
Principal Investigator
Facility Information:
Facility Name
Karolinska Institutet
City
Stockholm
ZIP/Postal Code
11330
Country
Sweden
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26506580
Citation
Mataix-Cols D, Fernandez de la Cruz L, Isomura K, Anson M, Turner C, Monzani B, Cadman J, Bowyer L, Heyman I, Veale D, Krebs G. A Pilot Randomized Controlled Trial of Cognitive-Behavioral Therapy for Adolescents With Body Dysmorphic Disorder. J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):895-904. doi: 10.1016/j.jaac.2015.08.011. Epub 2015 Sep 3.
Results Reference
background
Learn more about this trial
Internet-delivered Cognitive-behaviour Therapy for Adolescents With Body Dysmorphic Disorder
We'll reach out to this number within 24 hrs